| ORIGINAL ARTICLE |
|
| Year : 2023 | Volume
: 6
| Issue : 1 | Page : 26-35 |
|
|
Drug standardization and in vitro wound healing potential of Siddha herbomineral formulation Kandhaga Ennai for diabetic ulcers
Kehren R Rayma, Kirutisri Karthigeyan, Pooja Muniraj, Jeeva Gladys, Balagurusamy Karthigaeyam
Velumailu Siddha Medical College and Hospital, Sriperumbudur, Tamil Nadu, India
Correspondence Address:
Kehren R Rayma
Velumailu Siddha Medical College and Hospital, Kancheepuram, Sriperumbudur – 602 105, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jrsm.jrsm_7_23
|
|
|
Background: A serious and often expensive consequence of diabetes mellitus and diabetic foot ulcers are a major global source of death and morbidity. A diabetic patient’s lifetime risk of developing a foot ulcer has been estimated to be between 19 and 34%. Objective: The study drug Kandhaga Ennai (KE) selected from the Siddha classical text Rasavatha Manjari by P.M. Abdullah Saayabu is taken for preliminary assessing its wound healing potential of Ranamegangal (diabetic ulcers). Materials and Methods: The drug is prepared as per the method mentioned in the classic Siddha literature. KE is subjected to a sophisticated instrumental analysis such as Fourier transform infrared (FTIR) inductively coupled plasma optical emission spectrometry studies, a few physicochemical analytical parameters, and in vitro preclinical studies toward wound healing assays. Results: The study infers that all the toxic heavy metals are within range. KE has significant antioxidant activities reducing free radicals and effective antifungal property, and promotes migration and proliferation of fibroblasts. The results indicate that the herbomineral formulation may be useful in effective management of superficial wounds. Conclusion: This study validates the traditional claim of KE confirming the herbomineral formulation for anti-inflammatory, antioxidant, antimicrobial, and wound healing activities through in vitro methods. Additional experimental animal tests as well as clinical trials are required of this drug to treat diabetic ulcers. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
